60 DEGREES PHARMACEUTICALS, INC.

WASHINGTON, DC · Founded 2022 · Biotech · Private

Antiviral therapeutics targeting vector-borne diseases

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · 60degreespharma.com

Sector: Biotech
Headquarters: WASHINGTON, DC
Founded: 2022
Latest Form D: $1.1M, Feb 2025
Total capital: $9.7M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $3.9M; 3 Form D · last Feb 2025; 20 months since last filing
Federal contracts: $5.8M; 2 awards · Defense; Rank in Biotech#74 of 4373
Granted patents: 2; 6 pending · first 2026; Rank in peer group#397 of 1449

Capital timeline

Latest events

Feb 2025Private capital raisedForm D · SEC · 3rd filing$1.1M
Feb 2025Private capital raisedForm D · SEC · 2nd filing$1M
Jul 2024Federal contractDefense · Arakoda (tafenquine) Commercial Packaging And Validation$312K
May 2023Private capital raisedForm D · SEC · 1st filing$1.8M
Sep 2019Federal contractDefense · Brand Name Arakoda Malaria Prophylactic Drug Tafenoquine$5.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

45months

from 60 DEGREES PHARMACEUTICALS, INC.’s first federal award to its first private round.

First federal award · Sep 2019: Defense · $5.5M
First Form D · May 2023: $1.8M · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Geoffrey S. DowResearcherExecutive Officer, DirectorLinked by 2 patents
Charles Arlen Kiser, Jr.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 8

Jul 16, 2026PendingMethods To Treat Respiratory Infection Utilizing Castanospermine AnalogsUSPTOApplication 19560368
Jul 7, 2026GrantedMethods For The Treatment And Prevention Of Lung Infections Caused By SARS-COV-2 Virus By Administration Of TafenoquineUSPTOUS 12,673,053
Mar 10, 2026GrantedMethods To Treat Respiratory Infection Utilizing Castanospermine AnalogsUSPTOUS 12,569,473

Show all 8 patent records

Methods To Treat Respiratory Infection Utilizing Castanospermine AnalogsJul 16, 2026 · Application 19560368Pending
Methods For The Treatment And Prevention Of Lung Infections Caused By SARS-COV-2 Virus By Administration Of TafenoquineJul 7, 2026 · US 12,673,053Granted
Methods To Treat Respiratory Infection Utilizing Castanospermine AnalogsMar 10, 2026 · US 12,569,473Granted
Methods For The Treatment And Prevention Of Lung Infections Caused By Fungus By Administration Of TafenoquineJan 8, 2026 · Application 19294531Pending
Methods For The Treatment And Prevention Of Non-viral Tick-borne Diseases And Symptoms ThereofMar 6, 2025 · Application 18640695Pending
Methods For The Treatment And Prevention Of Diseases Or Infections With MCP-1 Involvement By Administration Of TafenoquineMay 23, 2024 · Application 18375070Pending
Methods For The Treatment And Prevention Of Lung Infections Caused By Gram-positive Bacteria, Fungus, Or Virus By Administration Of TafenoquineApr 25, 2024 · Application 18300805Pending
Methods For The Treatment And Prevention Of Non-viral Tick-borne Diseases And Symptoms ThereofApplication PCTUS2024025472Pending

REJUVENATE BIO INCSimilar federal contract value in Biotech · $6.3M in contracts
BCN BIOSCIENCES LLCSimilar federal contract value in Biotech · $6.2M in contracts
PAI LIFE SCIENCES INCSimilar federal contract value in Biotech · $5.8M in contracts
FABRICO TECHNOLOGY, INC.Similar federal contract value in Biotech · $5.6M in contracts
Shuttle Pharmaceuticals, Inc.Similar federal contract value in Biotech · $5.5M in contracts
Inhalon Biopharma, Inc.Similar federal contract value in Biotech · $5.4M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.